Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF L485W Ulixertinib gallbladder cancer sensitive detail...
BRAF D594N Binimetinib + Encorafenib gallbladder cancer predicted - sensitive detail...
MSH6 negative Dostarlimab-gxly gallbladder cancer sensitive detail...
MLH1 negative Dostarlimab-gxly gallbladder cancer sensitive detail...
MLH1 negative Pembrolizumab gallbladder cancer sensitive detail...
MSH6 negative Pembrolizumab gallbladder cancer sensitive detail...
RET fusion Pralsetinib gallbladder cancer sensitive detail...
RET fusion Selpercatinib gallbladder cancer sensitive detail...
BRAF V600E Dabrafenib + Trametinib gallbladder cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Terminated USA 0
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed USA | ITA 3
NCT02520141 Phase II Ramucirumab Ramucirumab for Advanced Pre-treated Biliary Cancers Completed USA 0
NCT02632305 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) Active, not recruiting CAN 0
NCT02711553 Phase II Ramucirumab Merestinib Cisplatin + Gemcitabine A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting USA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 10
NCT03093870 Phase II Capecitabine + Varlitinib Capecitabine Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Completed USA | ESP | AUS 8
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | ESP 1
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT04003636 Phase III Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT04057365 Phase II DKN-01 + Nivolumab A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Terminated USA 0
NCT04306367 Phase II Olaparib + Pembrolizumab Study of Pembrolizumab and Olaparib in Bile Duct Cancer Active, not recruiting USA 0
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed USA | ESP 4
NCT04466891 Phase II ZW25 A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01) Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN 3
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | BEL 3
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04781192 Phase Ib/II Durvalumab + Regorafenib The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Recruiting USA 0
NCT04907851 Phase II Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) Completed GBR | AUS 0
NCT04914286 Phase Ib/II GFH018 + Toripalimab-tpzi A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Completed AUS 1
NCT04976634 Phase II Belzutifan + Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Recruiting USA | NZL | NLD | FRA | ESP | BEL | AUS 3
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting USA 0
NCT05506943 Phase II Paclitaxel CTX-009 + Paclitaxel A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Recruiting USA 0
NCT05564403 Phase II Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Recruiting USA 0
NCT05862324 Phase Ib/II TAC01-CLDN18.2 TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) Recruiting USA | CAN 0
NCT06282575 Phase III Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + ZW25 Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + ZW25 Cisplatin + Gemcitabine + ZW25 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Recruiting USA 1
NCT06360354 Phase I AMG193 + Cisplatin + Gemcitabine + Pembrolizumab AMG193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AMG193 + Gemcitabine + Nab-paclitaxel A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion Recruiting USA 0